Coronavirus guidance by subject
Midlands and Lancashire Commissioning Support Unit
The list of resources will be updated as new material becomes available so please check back regularly for updates.
This page groups the resources by subject matter. The same list of resources is also available grouped by the organisation that issued it.
Latest
Thu 22 Oct COVID-19 prescribing briefing: corticosteroids
Thu 09 Jul Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older) (NHSEI)
Thu 09 Jul Vitamin D for COVID-19 [ES28] (NICE)
Thu 09 Jul Clinical guidance for healthcare professionals on maintaining immunisation programmes during COVID-19 (PHE)
Thu 09 Jul COVID-19 Therapeutic Alert: Dexamethasone in the treatment of COVID-19 (MHRA)
Thu 09 Jul Coronavirus (COVID-19): admission and care of people in care homes (GOV.UK)
Thu 09 Jul Analytical Collaboration for COVID-19 (The Strategy Unit, MLCSU)
Tue 16 Jun COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 [ES27] (NICE)
Tue 16 Jun Testosterone injection - administration and monitoring guidance (MLCSU)
Tue 16 Jun After-care needs of inpatients recovering from COVID-19 (NHSEI)
Therapeutic areas
Prescribing guidance
Operational guidance
Therapeutic areas
Anti-infective
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19 (NHSEI)
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (NICE, ES23)
- Asthma and COPD - oral steroid or antibiotic 'rescue packs' and extra steroid inhalers (RDTC guidance adopted by MLCSU)
- Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment (MHRA)
- Coronavirus - COVID 19 (CKS)
- COVID-19 prescribing briefing: corticosteroids (NICE)
- COVID-19 Primary Care Symptom Management Drug Therapy Options (NHS North West)
- COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 [ES24] (NICE)
- COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 [ES27] (NICE)
- COVID-19 Therapeutic Alert: Dexamethasone in the treatment of COVID-19 (MHRA)
- Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older) (NHSEI)
- Managing coronavirus (COVID-19) in general practice (SOP) (NHSEI)
- Notifiable diseases and causative organisms: how to report (PHE)
- Prescribing antibiotics for urgent dental care during sustained transmission of COVID 19 (BDA)
- Vitamin D and infection risk (RDTC guidance adopted by MLCSU)
- Vitamin D for COVID-19 [ES28] (NICE) Pan Mersey APC only
Blood and blood-forming organs
- COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis [ES26] (NICE)
- COVID-19 updates (British Society for Haematology)
- Vitamin B12 replacement (MLCSU)
Cardiovascular system
- Anticoagulation in cancer (RDTC guidance adopted by MLCSU)
- Coronavirus (COVID-19) and high blood pressure medication (MHRA)
- Coronavirus and you (British Heart Foundation)
- COVID-19 Clinicians Resource Hub (British Cardiovascular Society)
- COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 [ES24] (NICE)
- COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 [ES25] (NICE)
- Management of patients currently on warfarin during COVID-19 (SPS guidance adopted by MLCSU)
- Monitoring direct acting oral anticoagulants (DOACs) during the COVID-19 pandemic (RDTC guidance adopted by MLCSU)
- Practical guidance for patients infected with COVID-19 (Thrombosis UK)
Endocrine system
- Coronavirus and diabetes (Diabetes UK)
- COVID-19 and diabetes (Primary Care Diabetes Society)
- Prescribing in diabetes (RDTC guidance adopted by MLCSU)
- Type 1 and Type 2 diabetes and COVID-19 related mortality in England (NHSEI)
- Testosterone injection - administration and monitoring guidance (MLCSU)
Genito-urinary system
Immune system
Musculoskeletal system
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19 (NHSEI)
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (NICE, ES23)
- Disease modifying drugs: monitoring guidance (MLCSU)
- COVID-19: guidance for rheumatologists (British Society for Rheumatology)
- COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 [ES25] (NICE)
- Management of patients with musculoskeletal and rheumatic conditions on corticosteroids (NHSEI)
Nervous system
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19 (NHSEI)
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (NICE, ES23)
- COVID-19 guidance and advice (Association of British Neurologists)
- Depot antipsychotic injections: Administration during COVID-19 in stable adult patients (MLCSU)
- Lithium for stable adult patients: monitoring guidance. (MLCSU)
- Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (MHRA)
Nutrition and metabolic disorders
- Vitamin B12 replacement (MLCSU)
- Vitamin D and infection risk (RDTC guidance adopted by MLCSU)
- Vitamin D for COVID-19 [ES28] (NICE) Pan Mersey APC only
Respiratory system
- Asthma and COPD - oral steroid or antibiotic 'rescue packs' and extra steroid inhalers (RDTC guidance adopted by MLCSU)
- Community-based care of patients with chronic obstructive pulmonary disease (COPD) (NICE, NG168)
- Coronavirus and COVID-19 (British Lung Foundation)
- COVID-19 prescribing briefing: corticosteroids (NICE)
- COVID-19: information for the respiratory community (British Thoracic Society)
- Health advice for people with asthma (Asthma UK)
- Managing symptoms (including at the end of life) in the community (NICE, NG163)
- Managing suspected or confirmed pneumonia in adults in the community (NICE, NG165)
- Prescribing for Asthma and COPD guidance (RDTC guidance adopted by MLCSU)
- Respiratory inhalers (BTS)
Skin
- Advice for Dermatology HCPs during Covid-19 pandemic (British Association of Dermatologists)
Therapeutic drug monitoring
- Disease modifying drugs: monitoring guidance. (MLCSU)
- Lithium for stable adult patients: monitoring guidance. (MLCSU)
- Management of patients currently on warfarin during COVID-19 (SPS guidance adopted by MLCSU)
- Monitoring direct acting oral anticoagulants (DOACs) during the COVID-19 pandemic (RDTC guidance adopted by MLCSU)
Prescribing guidance
Prescribing in children
- Clinical guidelines for children and young people with palliative care needs in all care settings during the COVID19 pandemic (NHSEI)
- COVID-19 rapid guideline: children and young people who are immunocompromised [NICE NG174]
- Hospital Communication Passport and Supporting Resources (Include Me TOO)
- Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (RCPCH)
Prescribing in dental practice
Prescribing in palliative care
- Clinical guidelines for children and young people with palliative care needs in all care settings during the COVID19 pandemic (NHSEI)
- Collated list of resources for COVID-19 in palliative care (palliativedrugs.com)
- COVID-19 End of Life Anticipatory Care Plan – supporting information for Medicines Optimisation Teams (NHS North West)
- COVID-19 Primary Care Symptom Management Drug Therapy Options (NHS North West)
Operational guidance
Care homes
- Bulk Prescribing for Care Homes: A Guide for Care Home Teams (NHS North West)
- Care Home and Hospice Homely Remedy Guidance during COVID-19 (NHS North West)
- Care homes’ safe access and use of medicines: guidance, templates and flowcharts (NHS North West)
- Care Home Resource Hub (SPS)
- Care home support - locality template (NHS North West)
- Coronavirus (COVID-19): admission and care of people in care homes (GOV.UK)
- Coronavirus (COVID-19): support for care homes (DHSC)
- COVID-19 End of Life Anticipatory Care Plan – supporting information for Medicines Optimisation Teams (NHS North West)
- COVID-19 response: Identifying a clinical lead for all care homes (NHSEI)
- Direction to administer forms – use of electronic signatures during COVID-19 (SPS)
- Medication Acquisition Guidance during COVID-19 for Care Homes with Nursing and Hospices (NHS North West)
- Medication Acquisition Guidance during COVID-19 for Care Homes without Nursing (NHS North West)
- Pharmacy and Medicines Support to Care Homes: Urgent System-Wide Delivery Model (SPS)
- Prescribers obtaining Covid19 medicines for symptom control and treatment: guidance and templates (NHS North West)
- Reuse of Medicines in Northwest Care Homes during the COVID-19 Pandemic: Guidance and Resources (NHS North West)
- Working in care homes during COVID-19 (RPS)
Community pharmacy
- COVID-19 practical guidance and FAQs (RPS)
- Electronic Repeat Dispensing (Wessex Academic Health Science Network adopted by MLCSU)
- Ethical, professional decision making in the COVID-19 Pandemic (RPS)
- Guidance for Manufacturers Specials licence holders on ‘packing down’ medicines during the coronavirus (COVID-19) outbreak (MHRA)
- Pandemic delivery service (PSNC)
- Primary care pharmacy during the COVID pandemic (Primary Care Pharmacy Association)
- Q&A: Coronavirus (GPhC)
- Volunteers Guidance (RPS)
Finance
- Clinical Negligence Scheme for Coronavirus (NHS Resolution > Claims management)
- Revised arrangements for NHS contracting and payment during the COVID-19 pandemic (NHSEI > Finance)
General practice
- Advice on how to establish a remote ‘total triage’ model in general practice using online consultations (NHSEI)
- After-care needs of inpatients recovering from COVID-19 (NHSEI)
- Clinical guidance for healthcare professionals on maintaining immunisation programmes during COVID-19 (PHE)
- COVID-19 (British Medical Association)
- Electronic Repeat Dispensing (Wessex Academic Health Science Network adopted by MLCSU)
- Electronic Repeat Dispensing: Letter from Dr Nikita Kanani, Dr Keith Ridge and Ed waller: 4 June 2020 (NHSEI)
- Information for GPs advising both shielding and non shielding patients on support available during the COVID 19 pandemic (NHSEI)
- Managing coronavirus (COVID-19) in general practice (SOP) (NHSEI)
- Notifiable diseases and causative organisms: how to report (PHE)
- Primary care and community health support care home residents (NHSEI)
- Primary care pharmacy during the COVID pandemic (Primary Care Pharmacy Association)
- Principles of safe video consulting in general practice during COVID-19 (NHSEI)
- Shielded patients list: guidance for General Practice (NHS Digital)
Workforce
- Advice regarding NHS volunteers relating to COVID-19 (NHSEI)
- Community Pharmacy Volunteers Guidance (RPS)
- COVID-19 and Ramadan (NHS People)
- COVID-19 Supporting Guidance for prescribers working within COVID hubs and Medicine Conveyance with GP bags (NHS North West)
- Organisational Prescribing Code and EPS Guide for Primary Care (NHS North West)
- Ramadan rapid review (British Islamic Medical Association)
- Risks Assessment and Considerations – for setting up COVID-19 Hubs (NHS North West)
- Stay at home: guidance for households with possible coronavirus (COVID-19) infection (PHE)
Other resources
- Analytical Collaboration for COVID-19 (MLCSU The Strategy Unit, MLCSU)
- Coronavirus (COVID-19) hub (The BMJ)
- Coronavirus (COVID-19): reuse of medicines in a care home or hospice (NHSEI)
- Coronavirus guidance for clinicians and NHS managers (NHSEI)
- Coronavirus (COVID-19) (SPS)
- COVID-19 Supporting Guidance for prescribers working within COVID hubs and Medicine Conveyance with GP bags (NHS North West)
- MHRA regulatory flexibilities resulting from coronavirus (COVID-19)
- Our plan to rebuild: The UK Government’s COVID-19 recovery strategy (GOV.UK)
- Organisational Prescribing Code and EPS Guide for Primary Care (NHS North West)
- Resumption of dental services in England (NHSEI)
- Risks Assessment and Considerations – for setting up COVID-19 Hubs (NHS North West)
- Specialty guides (NHSEI)
- Second phase of NHS response to COVID-19: Letter from Sir Simon Stevens and Amanda Pritchard (NHSEI)
- Specialty-specific guidance on clinical care and treatment for COVID-19 (Royal College of Physicians)
- Stay at home: guidance for households with possible coronavirus (COVID-19) infection (PHE)
- The Misuse of Drugs (Coronavirus) (Amendments Relating to the Supply of Controlled Drugs During a Pandemic etc.) Regulations 2020 (GOV.UK)